Cargando…

Early offering transcatheter aortic valve replacement to patients with moderate aortic stenosis: quantifying costs and benefits – a Markov model-based simulation study

OBJECTIVE: Aortic stenosis (AS) is one of the most common acquired cardiac valvular diseases. The success of transcatheter aortic valve implantation (TAVI) for severe AS has led to increasing interest in its use to earlier disease—moderate AS (MAS). DESIGN: Model-based study using a Markov microsimu...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Dieu, Marwick, Tom, Moodie, Marj, Gao, Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668295/
https://www.ncbi.nlm.nih.gov/pubmed/37993164
http://dx.doi.org/10.1136/bmjopen-2023-073254
_version_ 1785149104750329856
author Nguyen, Dieu
Marwick, Tom
Moodie, Marj
Gao, Lan
author_facet Nguyen, Dieu
Marwick, Tom
Moodie, Marj
Gao, Lan
author_sort Nguyen, Dieu
collection PubMed
description OBJECTIVE: Aortic stenosis (AS) is one of the most common acquired cardiac valvular diseases. The success of transcatheter aortic valve implantation (TAVI) for severe AS has led to increasing interest in its use to earlier disease—moderate AS (MAS). DESIGN: Model-based study using a Markov microsimulation technique to evaluate the long-term costs and benefits associated with ‘early’ TAVI. Key data inputs were sourced from the international literature and costs were obtained from Australian sources. SETTING: Australian health care system perspective. PARTICIPANTS: 10 000 hypothetical MAS patients with or without left ventricular diastolic dysfunction or impaired left ventricular ejection fraction. INTERVENTION: Comparing early TAVI to medical management over a life time horizon for MAS patients aged >65 years. We evaluated the cost-effectiveness of offering early TAVI in five scenarios (10%, 25%, 50%, 75% and 90% take-up rates). PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome measure is quality-adjusted life years (QALY) gained and the incremental cost–utility ratio (ICUR). Secondary outcomes are life-years gained and the number of heart failure case avoided. RESULTS: Offering early TAVI for MAS patients resulted in both higher healthcare costs and greater benefits (an increase of 3.02 QALYs or 3.99 life-years) per person treated. The ICUR was around $A10 867 and $A11 926 per QALY gained for all five scenarios, with the total cost of early TAVI to the healthcare system being anticipated to be up to $A3.66 billion. Sensitivity analyses indicated a 100% probability of being cost-effective with a willingness to pay threshold of $A50 000/QALY. The benefits remained, even with assumptions of high levels of repeat valve replacement after TAVI. CONCLUSION: While ongoing randomised controlled trials will define the benefit of TAVI to MAS patients, these results suggest that this intervention is likely to be cost-effective.
format Online
Article
Text
id pubmed-10668295
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-106682952023-11-22 Early offering transcatheter aortic valve replacement to patients with moderate aortic stenosis: quantifying costs and benefits – a Markov model-based simulation study Nguyen, Dieu Marwick, Tom Moodie, Marj Gao, Lan BMJ Open Health Economics OBJECTIVE: Aortic stenosis (AS) is one of the most common acquired cardiac valvular diseases. The success of transcatheter aortic valve implantation (TAVI) for severe AS has led to increasing interest in its use to earlier disease—moderate AS (MAS). DESIGN: Model-based study using a Markov microsimulation technique to evaluate the long-term costs and benefits associated with ‘early’ TAVI. Key data inputs were sourced from the international literature and costs were obtained from Australian sources. SETTING: Australian health care system perspective. PARTICIPANTS: 10 000 hypothetical MAS patients with or without left ventricular diastolic dysfunction or impaired left ventricular ejection fraction. INTERVENTION: Comparing early TAVI to medical management over a life time horizon for MAS patients aged >65 years. We evaluated the cost-effectiveness of offering early TAVI in five scenarios (10%, 25%, 50%, 75% and 90% take-up rates). PRIMARY AND SECONDARY OUTCOME MEASURES: The primary outcome measure is quality-adjusted life years (QALY) gained and the incremental cost–utility ratio (ICUR). Secondary outcomes are life-years gained and the number of heart failure case avoided. RESULTS: Offering early TAVI for MAS patients resulted in both higher healthcare costs and greater benefits (an increase of 3.02 QALYs or 3.99 life-years) per person treated. The ICUR was around $A10 867 and $A11 926 per QALY gained for all five scenarios, with the total cost of early TAVI to the healthcare system being anticipated to be up to $A3.66 billion. Sensitivity analyses indicated a 100% probability of being cost-effective with a willingness to pay threshold of $A50 000/QALY. The benefits remained, even with assumptions of high levels of repeat valve replacement after TAVI. CONCLUSION: While ongoing randomised controlled trials will define the benefit of TAVI to MAS patients, these results suggest that this intervention is likely to be cost-effective. BMJ Publishing Group 2023-11-22 /pmc/articles/PMC10668295/ /pubmed/37993164 http://dx.doi.org/10.1136/bmjopen-2023-073254 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Health Economics
Nguyen, Dieu
Marwick, Tom
Moodie, Marj
Gao, Lan
Early offering transcatheter aortic valve replacement to patients with moderate aortic stenosis: quantifying costs and benefits – a Markov model-based simulation study
title Early offering transcatheter aortic valve replacement to patients with moderate aortic stenosis: quantifying costs and benefits – a Markov model-based simulation study
title_full Early offering transcatheter aortic valve replacement to patients with moderate aortic stenosis: quantifying costs and benefits – a Markov model-based simulation study
title_fullStr Early offering transcatheter aortic valve replacement to patients with moderate aortic stenosis: quantifying costs and benefits – a Markov model-based simulation study
title_full_unstemmed Early offering transcatheter aortic valve replacement to patients with moderate aortic stenosis: quantifying costs and benefits – a Markov model-based simulation study
title_short Early offering transcatheter aortic valve replacement to patients with moderate aortic stenosis: quantifying costs and benefits – a Markov model-based simulation study
title_sort early offering transcatheter aortic valve replacement to patients with moderate aortic stenosis: quantifying costs and benefits – a markov model-based simulation study
topic Health Economics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10668295/
https://www.ncbi.nlm.nih.gov/pubmed/37993164
http://dx.doi.org/10.1136/bmjopen-2023-073254
work_keys_str_mv AT nguyendieu earlyofferingtranscatheteraorticvalvereplacementtopatientswithmoderateaorticstenosisquantifyingcostsandbenefitsamarkovmodelbasedsimulationstudy
AT marwicktom earlyofferingtranscatheteraorticvalvereplacementtopatientswithmoderateaorticstenosisquantifyingcostsandbenefitsamarkovmodelbasedsimulationstudy
AT moodiemarj earlyofferingtranscatheteraorticvalvereplacementtopatientswithmoderateaorticstenosisquantifyingcostsandbenefitsamarkovmodelbasedsimulationstudy
AT gaolan earlyofferingtranscatheteraorticvalvereplacementtopatientswithmoderateaorticstenosisquantifyingcostsandbenefitsamarkovmodelbasedsimulationstudy